| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Revenue from collaboration and licensing | ||||||||
13,403 | 11,942 | 10,224 | 8,835 | 0 | - | 0 | 0 | - |
Operating expenses: | ||||||||
Research and development | ||||||||
47,659 | 46,312 | 39,748 | 34,893 | 27,175 | 21,965 | 0 | 0 | 0 |
General and administrative | ||||||||
18,633 | 16,715 | 13,720 | 10,413 | 8,075 | 6,844 | 0 | 0 | 0 |
Total operating expenses | ||||||||
0 | - | 0 | - | 0 | - | 0 | - | - |
Total operating expenses | ||||||||
- | - | - | 0 | - | - | - | 0 | 0 |
Loss from operations | ||||||||
-52,889 | -51,085 | -40,064 | -32,040 | -25,386 | -21,180 | 0 | 0 | 0 |
Other income (expense): | ||||||||
Grant income | ||||||||
7,017 | 6,737 | 4,389 | 4,893 | 4,733 | 5,612 | 0 | 0 | 0 |
Interest income | ||||||||
1,835 | 1,587 | 1,140 | 0 | 0 | - | - | 0 | - |
Interest expense | ||||||||
891 | 877 | 850 | 817 | 798 | 778 | 0 | 0 | 0 |
Other income and expenses, net | ||||||||
294 | 601 | 806 | 235 | 394 | 133 | 0 | 0 | 0 |
Total other income, net | ||||||||
8,255 | 8,048 | 5,485 | 4,886 | 4,393 | 4,967 | 0 | 0 | 0 |
Net loss before tax | ||||||||
-44,634 | -43,037 | -34,579 | -27,154 | -20,993 | -16,213 | 0 | 0 | 0 |
Income tax expense | ||||||||
0 | 0 | 154 | 147 | 48 | 24 | 0 | 0 | 0 |
Net loss | ||||||||
-44,634 | -43,037 | -34,685 | -27,253 | -20,993 | -16,237 | 0 | 0 | 0 |
Other comprehensive loss: | ||||||||
Foreign currency translation gain (loss), net of tax | ||||||||
-290 | -933 | -1,835 | -1,315 | -4,633 | -2,358 | 0 | 0 | 0 |
Comprehensive loss | ||||||||
-44,924 | -43,970 | -36,520 | -28,568 | -25,626 | -18,595 | 0 | 0 | 0 |
Net loss per share—basic and diluted | ||||||||
-0.43 | 7.94 | -0.45 | -0.63 | -9.27 | -2.02 | -4.34 | -6.38 | -5.02 |
Weighted average common shares outstanding — basic and diluted | ||||||||
25,630 | 25,783 | 25,408 | 19,240 | 1,006 | 922 | 911 | 911 | 911 |